According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- safety concerns about Xeljanz extended to Rinvoq and other Janus kinase (JAK) inhibitors;
- as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and
- therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.